Welcome to the e-CCO Library!

P615 Safety of vedolizumab in the treatment of IBD in a single tertiary centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Peruzzi, L. Calandrini, H. Privitera Hrustemovic, M. Salice, A. Decorato, A. Carbone, F. Rizzello, A. Belluzzi, E. Scaioli, C. Calabrese, P. Gionchetti

Created: Thursday, 30 January 2020, 10:12 AM
P615: Does smoking really influence the development and the outcomes of Inflammatory Bowel Disease in Asian population? Results from the Taiwanese patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Chen, B.C.(1);Weng, M.T.(2);Chang, C.H.(3);Huang, L.Y.(4);Wei, S.C.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P615: Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Kumagai*, M. Vinayaga-Pavan, I. Parisi, J. Barragry, R. Sundramoorthi, L. Whitley, H. Parker, R. Kettle, N. McCabrey, E. Seward, S. McCartney, S. Bloom, R. Vega, S. Mehta, F. Rahman

Created: Thursday, 21 February 2019, 9:14 AM
P615: Improving IBD monitoring by understanding preanalytical faecal calprotectin variability
Year: 2022
Source: ECCO'22
Authors: Schröder, O.(1,2);Farrag, K.(1,2);Böcher, A.(3);Helmschrodt, A.(3);Aksan, A.(2,4);Ehehalt, R.(5);Stein, J.M.(1,2,6);
Created: Friday, 11 February 2022, 3:56 PM
P615: Rescue infliximab for acute severe colitis: a single-centre experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Orpen-Palmer*1, F. Clegg1,2, U. Basavaraju1, G. H. Bain1, C. N. Parnaby1, M. G. Smith1, M. H. McLean1,2, J. M. Thomson1

Created: Friday, 22 February 2019, 9:41 AM
P615: The unfinished symphony: golimumab is efficient in patients with refractory Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Greener T., Greenberg G., Steinhart H., Silverberg M.

Created: Wednesday, 20 February 2019, 10:36 AM
P616 IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Young1, U. Freudensprung2, C. Harris1, R. Harris1, J. Harvey3, J. Addison4, S. Latter5, F. Cummings1

Created: Thursday, 30 January 2020, 10:12 AM
P616: Fatigue in pediatric inflammatory bowel diseases – systematic review and rates in a prospective cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Focht, G.(1)*;Turner, S.(2);Carmon, N.(1);Lev-Tzion, R.(1);Orlanski-Meyer, E.(1);Ledder, O.(1);Yogev, D.(1);Assa, A.(3);Turner, D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P616: Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tse C.S.*1, Deepak P.2, De La Fuente J.1, Murray J.2, Papadakis K.2

Created: Wednesday, 20 February 2019, 10:36 AM
P616: Safety of COVID-19 vaccines in patients with IBD
Year: 2022
Source: ECCO'22
Authors: Dussias, N.(1);Carbone, A.(1);Melotti, L.(1);Privitera Hrustemovic, H.(1);Salice, M.(1);Scaioli, E.(1);Calabrese, C.(1);Rizzello, F.(1);Gionchetti, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P616: Sustainability of thiopurines monotherapy in ulcerative colitis: a nationwide analysis from the epi-IIRN cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Friss, C.(1); Mendelovici, A.(1); Shteyer, E.(1); Orlanski-Meyer, E.(1); Ledderman, N.(2); Greenfeld, S.(3); Kariv, R.(3); Loewenberg Weisband, Y.(4);Gabay, H.(5); Nevo, D.(6); Matz, E.(7); Dotan, I.(8);Turner, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P616: Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Rao*1, R. Gadhok1, L. Whitley2, N. Burgess1, P. Amon1, S. Naik1, J. Lindsay1, S. McCartney2, K. Kok1

Created: Friday, 22 February 2019, 9:41 AM
P616: Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Leventi1,2, A. Aksan2,3*, J. Stein1,2, K. Farrag1,2

Created: Thursday, 21 February 2019, 9:14 AM
P617 Mesenchymal stromal cells of bone marrow reduce the risk of postoperative recurrence of Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. Knyazev, A.V. Kagramanova, A. Lishchinskaya, A. Parfenov

Created: Thursday, 30 January 2020, 10:12 AM
P617: Dual biologic therapy in pediatric Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Abbas, R.(1)*;Ibrahim, N.(1);Elawad, M.(1);Al-Mudahka, F.(1);Abdelrhman, H.(1);K.Akobeng, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P617: Evaluation of subclinical myocardial damage in patients with inflammatory bowel disease on treatment with biologics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Costantino*1, G. Mandraffino1, S. Tomeo1, A. Sitibondo1, M. Scolaro1, C. Zito2, G. Di Bella2, S. Loddo3, W. Fries1

Created: Friday, 22 February 2019, 9:41 AM
P617: Extraintestinal autoimmune phenomena during treatment with vedolizumab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lissner D.*1, Sonnenberg E.1, Glauben R.1, Allers C.1, Preiss J.1, Schneider T.1, Loddenkemper C.2, Siegmund B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P617: Single-centre experience with biological treatment in budesonide-refractory microscopic colitis patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Daferera1*, S. Ignatova2, A. Münch3

Created: Thursday, 21 February 2019, 9:14 AM
P617: Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with Inflammatory Bowel Disease: our experience in a tertiary hospital.
Year: 2022
Source: ECCO'22
Authors: Chivato Martín Falquina , I.(1);Saiz Chumillas , R.M.(1);Arias Garcia , L.(1);Vicente González , B.(2);Revilla Cuesta , N.(2);Alba Hernández , L.(1);Andrés Pascual , L.(1);Sicilia Aladrén , B.(1);
Created: Friday, 11 February 2022, 3:56 PM